STELLA PHARMA CORPORATION (JP:4888)

:4888

4888

STELLA PHARMA CORPORATION

RESEARCH TOOLSreports

Want to see JP:4888 full AI Analyst Report?

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)332.29K

Market Cap

¥10.69B

Enterprise Value¥10.07B

Total Cash (Recent Filing)¥2.85B

Total Debt (Recent Filing)¥727.12M

Price to Earnings (P/E)―

Beta0.94

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding35,034,100

10 Day Avg. Volume566,500

30 Day Avg. Volume332,290

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)10.64

Price to Sales (P/S)79.85

P/FCF Ratio-74.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsConsistently very high gross margins indicate the company’s products or services carry strong intrinsic profitability and pricing power. That margin cushion can absorb higher R&D or SG&A and supports the potential to reach operating profitability if revenue recovers or cost structure is rationalized.

Manageable LeverageModerate debt levels and a sizable equity base provide financial flexibility versus highly leveraged peers. Manageable leverage reduces near-term interest burden and makes it easier to fund operations, R&D or targeted investments without immediate solvency pressure.

Demonstrated Positive FCF YearA positive free cash flow year shows the underlying business can generate cash when revenue conditions are favorable. This suggests the company has the operational capacity to self-fund at least some investment and reduces long-term reliance on external capital if revenue stabilizes.

Bears Say

Structural UnprofitabilityDeep and persistent operating and net losses indicate the business has not yet achieved sustainable profitability. Long-term unprofitability erodes equity returns, limits internal reinvestment capacity, and increases the likelihood of dilution or financing needs to sustain operations and development programs.

Sharp Revenue ContractionA severe year-over-year revenue decline materially reduces visibility and undermines scalability of the high gross margins. Such volatility impedes planning, weakens customer or partner confidence, and makes it harder to achieve operating leverage necessary for long-term margin recovery.

Inconsistent Cash GenerationIrregular free cash flow creates recurring liquidity risk and the potential need for external financing. Cyclical or inconsistent cash generation constrains sustained R&D and commercialization spending, raising execution risk and the chance of capital raises that dilute existing holders.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥10.69B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

Currently, no data Available

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 35,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.